Argenx finalized its $2.2 billion acquisition of Forte Biosciences, while Novartis presented positive midstage inflammation data for pacibekitug. Meanwhile, AstraZeneca and Ionis suffered a late-stage trial failure for their heart disease drug eplontersen, and Deutsche Bank issued a sell rating for Novo Nordisk following pipeline delays.
01Company specific
argenx Completes Acquisition of Forte Biosciences for $77 Per Share
Absorbing a clinical-stage CD122 molecule hedges revenue concentration in Vyvgart by using existing balance-sheet cash to buy a second autoimmune pipeline anchor.
Argenx completed its acquisition of Forte Biosciences at a price of 77 dollars per share in cash. The transaction closed on August 27, 2026, following a tender offer in which 19,894,879 shares were validly tendered, representing approximately 87.13 percent of Forte's outstanding common stock. Argenx funded the acquisition entirely from its cash on hand, with total consideration reported at approximately $2.2 billion. Through a subsequent merger, Forte became a wholly owned subsidiary of Argenx and its shares were delisted from the Nasdaq Capital Market. The deal brings the antibody candidate FB102 into Argenx's immunology pipeline, adding a first-in-class anti-CD122 molecule with clinical data in vitiligo and celiac disease. Management positions the acquisition as part of the Vision 2030 strategy to expand beyond its flagship therapy Vyvgart.
FDA Seeks Public Input on Regulating Generative AI Medical Devices
Shift-planning for generative health tools toward clinician-style competency evaluations creates pre-market compliance hurdles that favor deep-pocketed platform incumbents over standalone point-solution startups.
The U.S. Food and Drug Administration has opened a public consultation on regulating medical devices powered by generative artificial intelligence, setting an October 19, 2026 comment deadline. While the agency has authorized over 1,000 conventional AI medical devices, generative systems introduce open-ended outputs, variable responses, and reliance on third-party foundation models that current regulatory frameworks do not fully address. The discussion paper outlines a proposed two-axis risk framework evaluating software function and the severity of potential harm from incorrect outputs, ranging from informational support to autonomous action. To address these challenges, the FDA is exploring a competency-based evaluation model inspired by human clinician credentialing, incorporating non-clinical benchmarking and clinical confirmation studies before market entry. The consultation does not establish binding policy or immediate new evidence requirements, but serves to gather stakeholder feedback on how to oversee technologies capable of producing hallucinations or variable clinical recommendations.
CRISPR Therapeutics to Pursue Highest Dose in Lipid Lowering Gene Therapy Trial
Sustained ANGPTL3 knockdowns without liver toxicity validate targeted gene editing as a viable single-dose alternative to chronic daily cardiovascular therapeutics.
CRISPR Therapeutics presented one-year durability data for its investigational gene editing therapy CTX310 at the European Society of Cardiology Congress 2026. A single intravenous infusion of the CRISPR-Cas9 therapy targeting ANGPTL3 produced a mean reduction in circulating ANGPTL3 of 79 percent with a maximum of 89 percent at the highest dose. Triglycerides fell by a mean of 48 percent with a maximum of 78 percent, while low-density lipoprotein dropped by a mean of 53 percent with a maximum of 84 percent. The Phase 1a trial evaluated single-course doses ranging from 0.1 to 0.8 milligrams per kilogram across 15 participants with lipid disorders. Treatment was well tolerated with no treatment-related serious adverse events or Grade 3 changes in liver transaminases. The company is advancing CTX310 in an ongoing Phase 1b trial and expects to provide an update on the severe hypertriglyceridemia cohort in the second half of 2026.
CTX310 Highest Dose Mean Reductions (%)
At the highest dose, ANGPTL3 dropped by 79 percent and LDL by 53 percent.
Novartis Evaluates Inflammation Drug for Cardiovascular Outcomes
Targeting interleukin-six to reduce cardiovascular risk shifts cardiac care toward inflammatory pathways, creating a new therapeutic class beyond traditional cholesterol-lowering mechanisms.
Novartis advanced pacibekitug after the antibody lowered signs of inflammation in a midstage study. Investigators reported dose-dependent drops in biomarker levels during the Phase 2 TRANQUILITY trial presented at the European Society of Cardiology annual meeting in Munich. The drug targets interleukin-6, a protein that regulates immune responses and drives inflammation. Experts are now waiting to see how the company plans to advance the treatment for cardiovascular use.
Novo Nordisk Seeks Chinese Approval for Oral Wegovy
Formulating semaglutide into a pill via SNAC absorption enhancers replaces cold-chain injection logistics with standard oral manufacturing, unlocking commercial scale across emerging markets.
China's drug regulator accepted Novo Nordisk's marketing application for an oral version of its Wegovy weight-loss drug. The tablet combines semaglutide with an absorption enhancer called SNAC to bypass the delivery challenges of peptide-based medicines. The filing accelerates a race against Eli Lilly, which submitted a marketing application for its competing oral GLP-1 pill, orforglipron, at the end of 2025. Local firm Innovent Biologics and Pfizer are also targeting the Chinese obesity market, where the National Health Commission projects the rate of overweight or obese individuals could exceed 65% by 2030. J.P. Morgan estimates Chinese sales of GLP-1 therapies could climb to 30 billion yuan from an estimated 3 billion to 4 billion yuan over the next five to seven years. Novo Nordisk has not disclosed a timeline for final regulatory clearance.
China GLP-1 Sales (Billion Yuan)
GLP-1 sales in China are projected to scale up nearly tenfold over time
Adding novel gene silencers on top of established protein stabilizers yields minimal incremental clinical benefit, weakening the pricing power and commercial underwriting for combination therapies in cardiomyopathy.
AstraZeneca and Ionis Pharmaceuticals reported that their gene-silencing drug eplontersen failed to show a statistically significant reduction in cardiovascular events or death in a late-stage heart disease study. The trial, called CARDIO-TTRansform, enrolled more than 1,400 volunteers with transthyretin-mediated amyloidosis cardiomyopathy over 140 weeks. Investigators found that 29% of patients taking eplontersen experienced cardiovascular events or death, compared to 32% of those given a placebo. Most participants in the study were already taking protein stabilizers, a standard-of-care medication type. The negative results raised questions about whether combining gene silencers with stabilizers provides meaningful incremental benefits. Alnylam Pharmaceuticals shares fell as much as 5% in morning trading following the data release, while AstraZeneca and Ionis stock prices ticked down about 1% and 2%.
CARDIO-TTRansform Trial Events (%)
Eplontersen showed no significant benefit over placebo in reducing events.
Deutsche Bank Issues First Sell Rating on Novo Nordisk Over Revenue Fears
Losing duopoly dominance in GLP-1 treatments exposes how single-class concentration converts pipeline setback revisions into structural revenue cliff re-ratings for mega-cap pharma.
Deutsche Bank issued the first major sell rating on Novo Nordisk, lowering its price target to 265 Danish kroner from 290 kroner as growth concerns mount. US shares declined about 2 percent following the downgrade, adding to a broader slide that has left the stock down roughly 70 percent from its June 2024 peak. Analyst Emmanuel Papadakis cited the failure of the late-stage cardiovascular trial for ziltivekimab, which removed the drug from future growth expectations and prompted mid-term revenue estimate cuts. The bank also pointed to intense competition from Eli Lilly in the GLP-1 obesity-drug market, pricing pressures in the United States, and limited upside from expanded Medicare coverage. Novo Nordisk faces further headwinds from upcoming patent expirations and increasing availability of lower-cost versions of Ozempic and Wegovy. The downgrade leaves investors weighing whether management can restore growth visibility ahead of an upcoming investor update.
Novo Nordisk Price Target Cut (DKK)
Deutsche Bank lowered its price target by 9 percent to 265 kroner.
Strong M&A and positive midstage data contrast sharply with high-profile late-stage trial failures and analyst downgrades. Whether regulatory frameworks for generative AI medical devices and fast-expanding Asian obesity markets can offset pipeline setbacks remains unresolved.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.